TB Alternative Assets Ltd. Increases Position in Regeneron Pharmaceuticals, Inc. $REGN

TB Alternative Assets Ltd. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 174.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,652 shares of the biopharmaceutical company’s stock after purchasing an additional 5,494 shares during the period. Regeneron Pharmaceuticals accounts for 0.7% of TB Alternative Assets Ltd.’s portfolio, making the stock its 27th largest position. TB Alternative Assets Ltd.’s holdings in Regeneron Pharmaceuticals were worth $4,865,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Marino Stram & Associates LLC increased its position in Regeneron Pharmaceuticals by 5.3% during the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 20 shares in the last quarter. Activest Wealth Management grew its stake in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the last quarter. CX Institutional increased its holdings in shares of Regeneron Pharmaceuticals by 7.9% during the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 22 shares in the last quarter. Independence Bank of Kentucky increased its holdings in shares of Regeneron Pharmaceuticals by 7.7% during the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock valued at $173,000 after acquiring an additional 22 shares in the last quarter. Finally, Redwood Wealth Management Group LLC raised its position in shares of Regeneron Pharmaceuticals by 4.8% in the 2nd quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 23 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Scotiabank boosted their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Finally, Guggenheim upped their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $779.45.

Regeneron Pharmaceuticals Stock Up 0.2%

REGN opened at $784.97 on Friday. The stock has a market capitalization of $82.50 billion, a price-to-earnings ratio of 18.80, a PEG ratio of 2.26 and a beta of 0.37. The firm has a 50 day moving average price of $703.50 and a 200-day moving average price of $610.25. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $792.77. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the company posted $12.46 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.